Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Nov 18, 2022

SELL
$71.48 - $86.85 $10,293 - $12,506
-144 Reduced 1.76%
8,053 $667,000
Q2 2021

Nov 18, 2022

BUY
$75.51 - $84.79 $261,944 - $294,136
3,469 Added 73.37%
8,197 $684,000
Q1 2021

Nov 18, 2022

SELL
$74.73 - $90.69 $1.4 Million - $1.7 Million
-18,742 Reduced 79.86%
4,728 $357,000
Q4 2020

Nov 18, 2022

SELL
$72.61 - $90.2 $1.12 Million - $1.39 Million
-15,459 Reduced 39.71%
23,470 $2.06 Million
Q3 2020

Nov 18, 2022

BUY
$71.87 - $131.03 $67,701 - $123,430
942 Added 2.48%
38,929 $2.96 Million
Q2 2020

Nov 18, 2022

SELL
$79.55 - $124.22 $37,308 - $58,259
-469 Reduced 1.22%
37,987 $4.69 Million
Q1 2020

Nov 18, 2022

BUY
$71.37 - $96.85 $15,630 - $21,210
219 Added 0.57%
38,456 $3.25 Million
Q4 2019

Nov 18, 2022

BUY
$64.27 - $86.37 $837,438 - $1.13 Million
13,030 Added 51.69%
38,237 $3.23 Million
Q3 2019

Nov 18, 2022

SELL
$67.4 - $85.11 $21,568 - $27,235
-320 Reduced 1.25%
25,207 $1.7 Million
Q2 2019

Nov 18, 2022

SELL
$80.35 - $93.9 $75,850 - $88,641
-944 Reduced 3.57%
25,527 $2.19 Million
Q1 2019

Nov 18, 2022

BUY
$84.2 - $98.62 $37,469 - $43,885
445 Added 1.71%
26,471 $2.35 Million
Q4 2018

Nov 18, 2022

SELL
$80.14 - $106.07 $104,182 - $137,891
-1,300 Reduced 4.76%
26,026 $2.22 Million
Q3 2018

Nov 18, 2022

SELL
$93.92 - $105.72 $52,595 - $59,203
-560 Reduced 2.01%
27,326 $2.65 Million
Q2 2018

Nov 18, 2022

BUY
$76.01 - $99.03 $721,182 - $939,596
9,488 Added 51.57%
27,886 $2.63 Million
Q1 2018

Nov 18, 2022

SELL
$77.67 - $92.63 $18,563 - $22,138
-239 Reduced 1.28%
18,398 $1.49 Million
Q4 2017

Nov 18, 2022

SELL
$80.76 - $95.13 $68,080 - $80,194
-843 Reduced 4.33%
18,637 $1.66 Million
Q3 2017

Nov 18, 2022

SELL
$80.6 - $94.95 $52,954 - $62,382
-657 Reduced 3.26%
19,480 $1.81 Million
Q2 2017

Nov 18, 2022

BUY
N/A
20,137
20,137 $1.83 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Citizens Business Bank Portfolio

Follow Citizens Business Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citizens Business Bank, based on Form 13F filings with the SEC.

News

Stay updated on Citizens Business Bank with notifications on news.